GT Bio: Positive Preclinical Data for GTB-5550 for Targeted Prostate Cancer Treatment

  GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE^® platform, today announced positive preclinical data in highlighting GTB-5550’s potential in prostate cancer. Martin Felices, PhD, Associate Professor of Medicine at the University of Minnesota, presented these data on Saturday, November 4th at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, which is being held in San Diego, California November 1-5.

https://www.biospace.com/article/releases/gt-biopharma-presented-positive-preclinical-data-for-gtb-5550-a-novel-trike-molecule-for-targeted-prostate-cancer-treatment-during-the-society-for-immunotherapy-of-cancer-sitc-2023-annual-meeting/